

**4th Annual
National Conference
September 21-23,
2023**

RhAPP
RHEUMATOLOGY ADVANCED
PRACTICE PROVIDERS



The background features a pattern of small, light-colored dots. Overlaid on this are several large, semi-transparent circles in shades of blue, orange, and grey. The text is centered within this design.

Individualizing Osteoporosis Treatment

Eileen Lydon, MSN, ANP
NYU Langone Orthopedic Hospital

Patty Travis, MSN, A/GNP
Cleveland Clinic

Accreditation Statement

All individuals in control of the content of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience all relevant financial relationships related to the content of the presentation or enduring material. Full disclosure of all relevant financial relationships will be made in writing to the audience prior to the activity. All other staff at the Annenberg Center for Health Sciences at Eisenhower and RhAPP have no relationships to disclose.

Faculty Disclosures

Eileen Lydon, ANP-BC

- Advisory Board: Novartis, Amgen, UCB

Patty Travis, CNP

- There are no relevant financial relationships to disclose.

Objectives

- Identify the most appropriate osteoporosis treatment selection based on case presentation
- Discuss possible adverse effects of various osteoporosis medications, weight the risks and benefits of treatment for specific patients and discuss perceived risks of rare major adverse effects of medications
- Communicate the imminent risk of future fractures in those with recent fragility fracture

Case #1

S.L. 57 yo female presents for an osteoporosis evaluation:

- Recent BMD
 - Femoral Neck T score -2.3
 - Lumbar Spine -2.7.
- FRAX Hip 1.3%, Major 7.3%
- No h/o fracture or falls
- No previous OP treatment
- Menarche 13, menopause 48
- No hot flashes
- Never used HRT
- No FH osteoporosis or parental hip fracture
- Mother with a hx. of breast cancer
- Daily milk drinker as a child
- No tobacco use , Social ETOH
- Denies hx of steroid use, thyroid disease, breast cancer or kidney stones.
- Takes calcium and vitamin d.

Case #1 – S.L., 57yo

Medical History

- PMH
 - Insomnia
 - GERD
- PSH
 - Denies
- Medications
 - Ambien PRN
 - Pepcid 20 mg daily

Workup

Labs

- PTH 30, Calcium 10
- Vitamin d 25 47
- C-telopeptide 186
- SPEP normal
- Creatinine 0.9
- Urine Calcium 100
- TSH – WNL

Discussion

- Should this patient be treated?
- If so, what are her treatment options?
- What plan would you discuss with this patient?

Raloxifene

Estrogen agonist/ antagonist

- Selective estrogen effect on the skeleton
- Anti-estrogenic effect on the breast
 - Decreases risk for breast cancer
- No increased risk of uterine cancer

MORE Trial

- Randomized 7705 women to PBO, Raloxifene 60 mg or 120mg for 3 years
- 30-50% reduction vertebral fracture risk
- No effect against non-vertebral fracture

Raloxifene (possible side effects)

- 3-fold increased risk of DVT/PE
- Increased mortality in women with stroke
 - No increased incidence of stroke or coronary events
- Increased hot flashes and night sweats

Case #1

- S.L. now age 68, continues on Raloxifene 60 mg daily. Her most recent bone density revealed RFN -2.7, Spine -2.7, c/w previous RFN T score -2.3, and Spine -2.7. She continues without falls or fractures, and no new medications or medical conditions. FRAX; Major osteoporotic 13%, Hip 3.5%
- Would you keep the same regimen?
- If change is made, what are your options?
- What is your treatment plan for this patient?

Bisphosphonates

- Bisphosphonates inhibit bone resorption
- Alendronate, Risendronate, Ibandronate and Zolendronic acid
- Reduction of vertebral fracture; 40-70%, non vertebral 20-35%, hip fracture 30-50%
 - Ibandronate reduces risk for vertebral fractures only
- Zolendronic acid given after hip fracture is associated with a 35% RR of new clinical fractures, and improved survival.

Bisphosphonates: Safety issues

- **Contraindications**
 - Hypocalcemia
 - Impaired renal function (GFR <30-35 ml/min)
 - If unable to take while fasting in AM, or able to wait upright for 30-60 minutes before eating (oral formulations only)
 - Esophagitis
- Zoledronic acid may cause acute phase reactions in up to 30% with first IV

What could go wrong?



Rare safety concerns

- Atypical femur fracture
 - Associated with long term use, higher in Asian population
- Osteonecrosis of the jaw
 - Less clear if duration dependent
- How do you educate your patients on these rare safety concerns ? Do you ever get resistance to start treatment due to these concerns?

Case #2

K.K. is a 55 yo female with PMH of uncontrolled diabetes, CAD, s/p MI 3/2022 (stent x 2), presented for a osteoporosis evaluation, s/p R THA 1/2023 due to hip fracture. She fell and fractured after slipping on a wet floor. This is her only known fracture, and she never took any bone strengthening medication.

- Bone density 1/2023 Spine -3.2, L hip – 2.7.
- Menarche age 14, Menopause age 53. G 13, P 9, Ab 4, and breast fed 12 of her children.
- Denies h/o steroid use, thyroid disease, kidney stones or breast cancer.
- Denies family history of osteoporosis or parental hip fracture.
- Takes supplemental calcium and vitamin D

Case #2 – K.K., 55yo

Medical History

- PMH
 - Uncontrolled DM
 - HL
 - CAD (MI, s/p stent x2)
- PSH
 - R THA
- Meds
 - Atorvastatin, clopidogrel, ASA, metoprolol, empaglutide, empagliflozin, metformin

Workup

- Vitamin d 25 - 52.5
- PTH – 57
- SPEP – WNL
- C-telopeptide – 234
- Calcium 10.1
- Creatinine 0.67
- Urine calcium 13.1
- IPEP – no monoclonal bands
- TSH 1.20

Discussion

- What are your thoughts about her fracture risk?
- What medication(s) would you discuss with this patient and why?

Who are the highest risk of fracture?


- Patients with recent clinical or new radiographic vertebral fracture
- Patients with a history of multiple fractures
- Patients with T score ≤ -3
 - Especially with other risk factors
 - Starting glucocorticoids

Imminent risk of a fracture, after prior fracture

- Incidence of imminent fracture after a prior fragility fracture was 7.58% in the first year and 11.58% in the first 2 years.
- Approximately half of re-fractures occurred in the first 2 years after a fragility fracture
- Older patients that have suffered from a fragility fracture should be treated promptly, to prevent the imminent risk of a fracture

Only 23% of patients receive osteoporosis medication after a hip fracture

A fracture is to osteoporosis what an acute myocardial infarction is to cardiovascular disease



Yusuf A, et al. Present at: ASBMR annual meeting. October 9-12, 2015; Seattle, WA. Abstract M00350

Faridi KF, et al. "Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction." JAMA Cardiol 2016;1 147-155

Treatment gap

- Treatment gap approximately 80% worldwide
- Morbidity, mortality, and health care costs of subsequent fx is higher than initial
- Studies show that patient's perceived risk of fracture low
- Important for HCP to initiate the conversation to counsel
- Fracture liaison services have been developed to better manage treatment

How to treat the very high risk

- Want to treat those with a recent fracture with agents that have the most rapid effect on fracture prevention
- Anabolic agents have a more rapid and greater fracture risk reduction compared with antiresorptive medications, especially in those at very high fracture risk

Anabolic Agents

- Which one would you choose and why?
 - Teriparatide
 - Abaloparatide
 - Romosozumab

Teriparatide and Abaloparatide

- Safety issues:
 - Rodent osteosarcoma – Boxed warning and 24 month cumulative use restriction removed from PI
 - Hypercalcemia (transient), and hypercalciuria (minimal)
 - Orthostatic hypotension – dizziness, tachycardia, nausea
 - Erythema at injection site
 - Leg cramps/musculoskeletal pains/fatigue

Case Study #3 – H.G.

- 48 yo female, BMD 5/2023
 - LS (L1-L4) T-score -2.2
 - L total hip T-score -2.3
 - L fem neck T-score -2.9

New OP. No previous treatment.

What's your first thought on treatment?

What do you want to know?

Case Study #3 – H.G., 48 yo



Clinical Pearl: Steepest decline in bone loss the first 5 yrs after menopause

- Key History

- Works as OT
- No falls or fx
- No smoking or etoh use
- No transplant hx
- Good dentition

- OP Risk Factors

- Wt <127, Ht 4' 11"
- FHx +OP (mother)
- Menarche, 13
- Menopause, **47**
- G 4, P 4, Ab 0
(youngest 8yo & 10yo)

Any changes to your treatment plan?

Case Study #3 – H.G.

- 48 yo female, BMD 5/2023
 - LS (L1-L4) T-score -2.2; SS interval decrease -8.1%
 - L total hip T-score -2.3; SS -10.5%
 - L fem neck T-score -2.9; SS -11.4%

Osteopenia a year ago. Thoughts?

- BMD 5/2022
 - LS (L1-L4) T-score -1.5
 - L total hip T-score -1.7
 - L fem neck T-score -2.3

What else do you want to know?

Case Study #3 – H.G.

PMH – no CV hx

- Epilepsy

- anti-convulsants since age 18

- GERD

- Famotidine PRN

- UCTD

- HCQ & MTX, 2019
- Limited pred since 2019
(dose pack, 5mg PRN)

- Breast CA, 2020

- Bilat mastectomy, Jan
- Chemo & Radiation
- Tamoxifen (SERM), Aug

- Total Hysterectomy, 12/2021

- Tamoxifen changed to
Anastrozole (AI), May 2022

Benefits of Treatment Choice

Anabolic

Significant BMD advantage

- PTH underestimated by DXA
- Romo 1-yr hip +6%

Clear fracture advantage

- Vertebral
- Non-vertebral and hip

Morphometric

- Cortical thickening
- Trabecular connectivity

Foundational effect

- Lower fx rates with AR agent after anabolic

Antiresorptive

Easy to use

Less expensive

No 2-year limitation

Extension trials

- 10 yrs denosumab
- 10 yrs for alendronate

Duration

- 3-10 yrs, holiday, retreat

Romosozumab Background


- Monoclonal antibody that binds and inhibits sclerostin
- Sclerostin inhibition has dual effect on bone
 - Stimulates bone formation by promoting osteoblast number and activity
 - Reduces bone resorption by inhibiting RANK ligand expression
 - Increases BMD markedly
- Phase 3 Trials
 - FRAME: randomized, blinded, placebo-controlled for 1 year followed by denosumab for 1 year in all¹
 - ARCH: randomized, blinded romosozumab vs alendronate for 1 year followed by alendronate for all² (black box warning on CV events from this study)
 - STRUCTURE: alendronate treated women randomized to romosozumab vs teriparatide³

1. Cosman F, et al. *N Engl J Med.* 2016;375:1532-1543.

2. Saag K, et al. *N Engl J Med* 2017;377:1417-1427.

3. Langdahl B, et al. *Lancet* 2017

Treatment Sequencing Matters ARCH Trial







Saag KG, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. *N Engl J Med.* 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. PMID: 28892457.

Antiresorptive after Anabolics

Percentage change from baseline in BMD at the lumbar spine (A, B) and total hip (C, D) through month 36.

— Romosozumab 210 mg QM^a — Alendronate 70 mg QW^a - - - Denosumab 60 mg Q6M^b
— Pooled Placebo^a — Romosozumab 140 mg QM^a - - - Placebo Q6M^b



Safety Considerations for Anabolic Agents

Teriparatide/Abaloparatide

- Rodent osteosarcoma (no increase in 15 year follow up with teriparatide)
- Hypercalcemia and hypercalciuria
- Orthostatic hypotension-dizziness, tachycardia, nausea
- Erythema at injection site
- Leg cramps/musculoskeletal pains/fatigue

Romosozumab



- Injection site reactions
- Hypersensitivity
- Hypocalcemia
- MI, CVA, CV Death Imbalance in ARCH but not FRAME

BMD Increases



Clinical Pearl: Gains lost if not followed up with antiresorptive

FRAME (Romozosumab) vs Freedom (Denosumab)



BMD increases

BMD Changes LS

Romo 1 years
Dmab >4.5 years

BMD Changes LS

Romo-Dmab 2 years
Dmab alone 7 years

BMD Changes Hip

Romo-Dmab 2 years
Dmab alone >6.5 years

Case #4



Clinical Pearl: OP with/ from PHPT, preferentially seen in the distal forearm, which is rich in cortical bone

78 yo female with PMH of DM2, CHF, COPD on 3L O2, h/o lung carcinoid s/p resection 2009, CKD 3-4, HLD, thyroid cancer s/p TT 2009, postoperative hypothyroidism, OSA, HPT

– BMD 4/2022

- L Fem Neck: T-Score -2.8; L Hip: T-Score -2.0
- Distal 1/3 R Forearm: T-Score -3.0

Denosumab administered

- **5/3/22**
- **11/2/22**
- **5/3/23**

Bone Labs	2/24/2022	5/26/2022	6/21/2022	9/8/2022	2/3/2023	5/26/2023
PTH, Intact	299 (H)	1,081 (H)	214 (H)	240 (H)	250 (H)	514 (H)
Vitamin D25	21.2 (L)		20.5 (L)	38.0	22.5 (L)	29.6 (L)
Vit D1,25					47.1	71.8

Calcium

Pre-Dmab	10.8 (4/22)	10.3 (10/22)	10.0 (5/23)
Post-Dmab	8.6 (5/22)	9.3 (11/15/22)	8.1 (6/9/23)
Post-post-Dmab		10.9 (11/30/22)	10.8 (7/18/23)

Wood K, et al. Oncologist. 2012;17(3):322-5.

Discussion

- Why was denosumab chosen for this pt
- How to manage hypocalcemia in the setting of CKD
- How long to expect hypocalcemia

* Clinical Pearl

PTH in CKD

Stage 3: 35-70

Stage 4: 70-110

Stage 5: 150-300

Denosumab Considerations

* Clinical Pearl
ONJ statistically the same as
being killed by lightning

- Significantly reduces the risk of vertebral and nonvertebral fractures
- Patients who discontinue denosumab are at increased risk for rebound vertebral fractures, often multiple fx & can occur as soon as 8 months after the last injection
- Providers should consider the patient's ability to adhere to regular, timely dosing and counsel the pt about possibility of rebound fx & against discontinuation without medical consultation
- Possible rare risk of ONJ and AFF

Transitioning from Denosumab to Bisphosphonate

Summary of Recommendations Regarding the Discontinuation of Denosumab

- If long-term denosumab is stopped, patients should be transitioned to a bisphosphonate, with either
 - a single-dose of zoledronic acid 6 months from the last denosumab dose, or
 - a short course (at least 1 year) of oral alendronate

Monitor serum CTX or urine NTX and BMD and re-dose if bone turnover markers are persistently elevated or if BMD shows a significant decline

References

- Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med*. 2007 Nov 1;357(18):1799-809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17. PMID: 17878149; PMCID: PMC2324066.
- Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. *JAMA*. 1999 Aug 18;282(7):637-45. doi: 10.1001/jama.282.7.637. Erratum in: *JAMA* 1999 Dec 8;282(22):2124. PMID: 10517716.
- Wong RMY, Wong PY, Liu C, Wong HW, Chung YL, Chow SKH, Law SW, Cheung WH. The imminent risk of a fracture-existing worldwide data: a systematic review and meta-analysis. *Osteoporos Int*. 2022 Dec;33(12):2453-2466. doi: 10.1007/s00198-022-06473-0. Epub 2022 Jul 1. PMID: 35776148.
- Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. *JAMA Cardiol*. 2016 May 1;1(2):147-55. doi: 10.1001/jamacardio.2016.0001. PMID: 27437885.

References

- Cosman F. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. *Endocr Pract.* 2020 Jul;26(7):777-786. doi: 10.4158/EP-2019-0596. Epub 2020 Nov 24. PMID: 33471647.
- Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM; FNIH Bone Quality Project. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. *J Bone Miner Res.* 2019 Apr;34(4):632-642. doi: 10.1002/jbmr.3641. Epub 2019 Jan 23. PMID: 30674078.
- Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML; Foundation for the National Institutes of Health Bone Quality Project. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. *Lancet Diabetes Endocrinol.* 2020 Aug;8(8):672-682. doi: 10.1016/S2213-8587(20)30159-5. Erratum in: *Lancet Diabetes Endocrinol.* 2020 Oct;8(10):e5. PMID: 32707115.

References

- Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. *N Engl J Med*. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. PMID: 28892457.
- Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. *J Bone Miner Res*. 2019 Mar;34(3):419-428. doi: 10.1002/jbmr.3622. Epub 2018 Dec 3. PMID: 30508316.
- McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. *J Bone Miner Res*. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22. PMID: 29694685.
- Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. *J Bone Miner Res*. 2018 Jul;33(7):1219-1226. doi: 10.1002/jbmr.3427. Epub 2018 May 17. PMID: 29573473.

References

- Wood K, Dhital S, Chen H, Sippel RS. What is the utility of distal forearm DXA in primary hyperparathyroidism? *Oncologist*. 2012;17(3):322-5. doi: 10.1634/theoncologist.2011-0285. Epub 2012 Jan 18. PMID: 22258698; PMCID: PMC3316917.
- Eremkina A, Krupinova J, Dobрева E, Gorbacheva A, Bibik E, Samsonova M, Ajnetdinova A, Mokrysheva N. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. *Endocr Connect*. 2020 Oct;9(10):1019-1027. doi: 10.1530/EC-20-0380. PMID: 33112830; PMCID: PMC7707828.
- Symonds C, Kline G. Warning of an increased risk of vertebral fracture after stopping denosumab. *CMAJ*. 2018 Apr 23;190(16):E485-E486. doi: 10.1503/cmaj.180115. PMID: 29685907; PMCID: PMC5915244.
- Tay WL, Tay D. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature. *Endocrinol Metab (Seoul)*. 2022 Apr;37(2):183-194. doi: 10.3803/EnM.2021.1369. Epub 2022 Apr 14. PMID: 35417954; PMCID: PMC9081316.